PRESS RELEASE

REPORT ON THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN S.P.A.

Saluggia, August 7, 2026 – With reference to treasury shares buy-back plan disclosed to the market and launched on January 27, 2026 as authorized by the Shareholders' meeting on the same date – on the basis of the information provided by Bank of America Securities Europe SA as intermediary in charge of executing, in full independency the share buy-back program in the name and on behalf of the Company – Diasorin hereby announces that, during the period from August 3, 2026 to August 7, 2026, no. 1 treasury share for a total consideration of 72.38 Euro were purchased.

Aggregate details of the daily purchases of Diasorin S.p.A. ordinary shares (ISIN IT0003492391) are as follows:

Date	Trading Venue	Number of ordinary shares purchased	Average price (Euro)	Consideration (Euro)
August 3, 2026	MTAA	1	72.38	72.38
Total	**MTAA**	**1**	**72.38**	**72.38**

In accordance with the provisions of Article 2 paragraph 3 of the EU Regulation 1052, attached to this press release, information of the daily buying-in operations carried out in the above-mentioned period is indicated in detail.

Following the above purchases and considering the treasury shares already in portfolio, as of August 7, 2026, Diasorin S.p.A. holds no. 6,505,767 treasury shares, equal to 11.63% of the share capital.

About Diasorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava
Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo
Corporate Investor Relations & ESG Senior Analyst
eugenia.ragazzo@diasorin.com

Date	Transaction Time	Trading Venue	Number of ordinary shares purchased	Average Price (EUR)	Consideration (EUR)	Transaction Reference Number
03-Aug-26	09:01:37	MTAA	1	72,3800	72,4	0XL0411000000000346NAI